Prof. Dr. med. et phil. nat. Markus Jörger
chief of service
Medizinische Onkologie und Hämatologie · Dept. I
SAKK 19/17: safety analysis of first-line durvalumab in patients with PD-L1 positive, advanced nonsmall cell lung cancer and a performance status of 2
Mark M, Früh M, Biaggi-Rudolf C, Weindler S, Baudoux N, Schwitter M, Wannesson L, Jörger M, Metaxas Y, Schneider M, Friedlaender A, Burmeister H, Janthur W, Rothschild S, Pless M, Addeo A, Eboulet E, Froesch P, Swiss Group for Clinical Cancer Research (SAKK). SAKK 19/17: safety analysis of first-line durvalumab in patients with PD-L1 positive, advanced nonsmall cell lung cancer and a performance status of 2. Cancer Immunol Immunother 2020
Nov 1, 2020SAKK 19/17: safety analysis of first-line durvalumab in patients with PD-L1 positive, advanced nonsmall cell lung cancer and a performance status of 2
Nov 1, 2020Cancer Immunol Immunother 2020
Mark Michael, Früh Martin, Biaggi-Rudolf Christine, Weindler Susanne, Baudoux Nathalie, Schwitter Michael, Wannesson Luciano, Jörger Markus, Metaxas Yannis, Schneider Martina, Friedlaender Alex, Burmeister Henning, Janthur Wolf-Dieter, Rothschild Sacha I, Pless Miklos, Addeo Alfredo, Eboulet Eric Innocents, Froesch Patrizia, Swiss Group for Clinical Cancer Research (SAKK)
A Novel Nomenclature for Repeat Motifs in the Thymidylate Synthase Enhancer Region and Its Relevance for Pharmacogenetic Studies
Schaerer D, Froehlich T, Hamzic S, Offer S, Diasio R, Jörger M, Amstutz U, Largiadèr C. A Novel Nomenclature for Repeat Motifs in the Thymidylate Synthase Enhancer Region and Its Relevance for Pharmacogenetic Studies. J Pers Med 2020; 10
Oct 19, 2020A Novel Nomenclature for Repeat Motifs in the Thymidylate Synthase Enhancer Region and Its Relevance for Pharmacogenetic Studies
Oct 19, 2020J Pers Med 2020; 10
Schaerer Dominic, Froehlich Tanja K, Hamzic Seid, Offer Steven M, Diasio Robert B, Jörger Markus, Amstutz Ursula, Largiadèr Carlo R
Time-to-Event Analysis of Paclitaxel-Associated Peripheral Neuropathy in Advanced Non-Small-Cell Lung Cancer Highlighting Key Influential Treatment/Patient Factors
Ojara F, Henrich A, Frances N, Huisinga W, Hartung N, Jörger M, Kloft C. Time-to-Event Analysis of Paclitaxel-Associated Peripheral Neuropathy in Advanced Non-Small-Cell Lung Cancer Highlighting Key Influential Treatment/Patient Factors. J Pharmacol Exp Ther 2020; 375:430-438.
Oct 2, 2020Time-to-Event Analysis of Paclitaxel-Associated Peripheral Neuropathy in Advanced Non-Small-Cell Lung Cancer Highlighting Key Influential Treatment/Patient Factors
Oct 2, 2020J Pharmacol Exp Ther 2020; 375:430-438
Ojara Francis W, Henrich Andrea, Frances Nicolas, Huisinga Wilhelm, Hartung Niklas, Jörger Markus, Kloft Charlotte
Obesity Alters Endoxifen Plasma Levels in Young Breast Cancer Patients: A Pharmacometric Simulation Approach
Mueller-Schoell A, Schwab M, Zgheib N, Tfayli A, Chowbay B, Chen S, Eccles D, Copson E, Mathijssen R, Koolen S, Neven P, Jörger M, Huisinga W, Brauch H, Michelet R, Mürdter T, Schroth W, Klopp-Schulze L, Kloft C. Obesity Alters Endoxifen Plasma Levels in Young Breast Cancer Patients: A Pharmacometric Simulation Approach. Clin Pharmacol Ther 2020; 108:661-670.
Jul 23, 2020Obesity Alters Endoxifen Plasma Levels in Young Breast Cancer Patients: A Pharmacometric Simulation Approach
Jul 23, 2020Clin Pharmacol Ther 2020; 108:661-670
Mueller-Schoell Anna, Schwab Matthias, Zgheib Nathalie K, Tfayli Arafat, Chowbay Balram, Chen Sylvia, Eccles Diana, Copson Ellen, Mathijssen Ron H J, Koolen Stijn L W, Neven Patrick, Jörger Markus, Huisinga Wilhelm, Brauch Hiltrud, Michelet Robin, Mürdter Thomas, Schroth Werner, Klopp-Schulze Lena, Kloft Charlotte
Prognostic value of tumor-infiltrating lymphocytes (TILs) and their association with PD-L1 expression and DNA repair protein RAD51 in patients with resected non-small cell lung carcinoma
Gachechiladze M, Soltermann A, Rulle U, Weder W, Stahel R, Kolář Z, Shani I, Hajduch M, Vbrková J, Vojta P, Smičková P, Kolek V, Überall I, Skanderová D, Škarda J, Jörger M. Prognostic value of tumor-infiltrating lymphocytes (TILs) and their association with PD-L1 expression and DNA repair protein RAD51 in patients with resected non-small cell lung carcinoma. Lung Cancer 2020; 147:30-38.
Jun 23, 2020Prognostic value of tumor-infiltrating lymphocytes (TILs) and their association with PD-L1 expression and DNA repair protein RAD51 in patients with resected non-small cell lung carcinoma
Jun 23, 2020Lung Cancer 2020; 147:30-38
Gachechiladze Mariam, Soltermann Alex, Rulle Undine, Weder Walter, Stahel Rolf, Kolář Zdeněk, Shani Ilay, Hajduch Marian, Vbrková Jana, Vojta Petr, Smičková Petra, Kolek Vítězslav, Überall Ivo, Skanderová Daniela, Škarda Josef, Jörger Markus
Integrated Data Analysis of Six Clinical Studies Points Toward Model-Informed Precision Dosing of Tamoxifen
Klopp-Schulze L, Mueller-Schoell A, Neven P, Koolen S, Mathijssen R, Jörger M, Kloft C. Integrated Data Analysis of Six Clinical Studies Points Toward Model-Informed Precision Dosing of Tamoxifen. Front Pharmacol 2020; 11:283.
Mar 31, 2020Integrated Data Analysis of Six Clinical Studies Points Toward Model-Informed Precision Dosing of Tamoxifen
Mar 31, 2020Front Pharmacol 2020; 11:283
Klopp-Schulze Lena, Mueller-Schoell Anna, Neven Patrick, Koolen Stijn L W, Mathijssen Ron H J, Jörger Markus, Kloft Charlotte
Evaluating the role of ENOSF1 and TYMS variants as predictors in fluoropyrimidine-related toxicities: An IPD meta-analysis
Hamzic S, Amstutz U, López-Fernández L, García-González X, Schellens J, Meulendijks D, Thomlinson I, Palles C, Aebi S, Jörger M, Froehlich T, Kummer D, Largiadèr C. Evaluating the role of ENOSF1 and TYMS variants as predictors in fluoropyrimidine-related toxicities: An IPD meta-analysis. Pharmacol Res 2019; 152:104594.
Dec 12, 2019Evaluating the role of ENOSF1 and TYMS variants as predictors in fluoropyrimidine-related toxicities: An IPD meta-analysis
Dec 12, 2019Pharmacol Res 2019; 152:104594
Hamzic Seid, Amstutz Ursula, López-Fernández Luis A, García-González Xandra, Schellens Jan H M, Meulendijks Didier, Thomlinson Ian, Palles Claire, Aebi Stefan, Jörger Markus, Froehlich Tanja K, Kummer Dominic, Largiadèr Carlo R
Phase 1 Dose Escalation Study of the Allosteric AKT Inhibitor BAY 1125976 in Advanced Solid Cancer-Lack of Association between Activating AKT Mutation and AKT Inhibition-Derived Efficacy
Schneeweiss A, Lagkadinou E, Wilkinson G, Boix O, Thiele S, Rudolph M, Rentzsch C, Hurvitz S, Ma C, Tsimberidou A, Moulder S, Varga A, Jörger M, Hess D, Ocker M. Phase 1 Dose Escalation Study of the Allosteric AKT Inhibitor BAY 1125976 in Advanced Solid Cancer-Lack of Association between Activating AKT Mutation and AKT Inhibition-Derived Efficacy. Cancers (Basel) 2019; 11
Dec 10, 2019Phase 1 Dose Escalation Study of the Allosteric AKT Inhibitor BAY 1125976 in Advanced Solid Cancer-Lack of Association between Activating AKT Mutation and AKT Inhibition-Derived Efficacy
Dec 10, 2019Cancers (Basel) 2019; 11
Schneeweiss Andreas, Lagkadinou Eleni, Wilkinson Gary, Boix Oliver, Thiele Silke, Rudolph Marion, Rentzsch Christine, Hurvitz Sara A, Ma Cynthia, Tsimberidou Apostolia M, Moulder Stacy, Varga Andrea, Jörger Markus, Hess Dagmar, Ocker Matthias
Contrasting evidence to reimbursement reality for off-label use (OLU) of drug treatments in cancer care: rationale and design of the CEIT-OLU project
Herbrand A, Hemkens L, Sricharoenchai S, Novak U, Mc Cord K, Jörger M, Hoogkamer A, Ewald H, Diem S, Briel M, Schmitt A, Kasenda B. Contrasting evidence to reimbursement reality for off-label use (OLU) of drug treatments in cancer care: rationale and design of the CEIT-OLU project. ESMO Open 2019; 4:e000596.
Dec 1, 2019Contrasting evidence to reimbursement reality for off-label use (OLU) of drug treatments in cancer care: rationale and design of the CEIT-OLU project
Dec 1, 2019ESMO Open 2019; 4:e000596
Herbrand Amanda Katherina, Hemkens Lars G, Sricharoenchai Sirintip, Novak Urban, Mc Cord Kimberly Alba, Jörger Markus, Hoogkamer Anouk, Ewald Hannah, Diem Stefan, Briel Matthias, Schmitt Andreas Michael, Kasenda Benjamin
A Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma
van den Bent M, Zhang H, Balbin O, Vicente S, Cheng Y, Kirsilae T, Zhao S, Tiedt R, Rodón J, Tabatabai G, Jörger M, Lassman A, Wen P, Yung W, Sepulveda J, De Vos F, Azaro A, Wick W. A Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma. J Neurooncol 2019
Nov 27, 2019A Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma
Nov 27, 2019J Neurooncol 2019
van den Bent Martin, Zhang Hefei, Balbin O Alejandro, Vicente Sergio, Cheng Yi, Kirsilae Tiina, Zhao Sylvia, Tiedt Ralph, Rodón Jordi, Tabatabai Ghazaleh, Jörger Markus, Lassman Andrew B, Wen Patrick Y, Yung W K Alfred, Sepulveda Juan, De Vos Filip, Azaro Analia, Wick Wolfgang
Predictive impact of antibiotics in patients with advanced non small-cell lung cancer receiving immune checkpoint inhibitors : Antibiotics immune checkpoint inhibitors in advanced NSCLC
Schett A, Rothschild S, Curioni-Fontecedro A, Krähenbühl S, Früh M, Schmid S, Driessen C, Jörger M. Predictive impact of antibiotics in patients with advanced non small-cell lung cancer receiving immune checkpoint inhibitors : Antibiotics immune checkpoint inhibitors in advanced NSCLC. Cancer Chemother Pharmacol 2019; 85:121-131.
Nov 19, 2019Predictive impact of antibiotics in patients with advanced non small-cell lung cancer receiving immune checkpoint inhibitors : Antibiotics immune checkpoint inhibitors in advanced NSCLC
Nov 19, 2019Cancer Chemother Pharmacol 2019; 85:121-131
Schett Anne, Rothschild Sacha I, Curioni-Fontecedro Alessandra, Krähenbühl Stephan, Früh Martin, Schmid S, Driessen Christoph, Jörger Markus
Safety, Tolerability, and Potential Clinical Activity of a Glucocorticoid-Induced TNF Receptor-Related Protein Agonist Alone or in Combination With Nivolumab for Patients With Advanced Solid Tumors: A Phase 1/2a Dose-Escalation and Cohort-Expansion Clinical Trial
Heinhuis K, Schilder R, O'Byrne K, Curigliano G, Romano E, Patah P, Wang R, Liu Y, Bajaj G, Britschgi C, Paz-Ares L, Carlino M, Jörger M, Di Nicola M, Meniawy T, Rottey S, Moreno V, Gazzah A, Delord J, Siu L. Safety, Tolerability, and Potential Clinical Activity of a Glucocorticoid-Induced TNF Receptor-Related Protein Agonist Alone or in Combination With Nivolumab for Patients With Advanced Solid Tumors: A Phase 1/2a Dose-Escalation and Cohort-Expansion Clinical Trial. JAMA Oncol 2019:1-8.
Nov 7, 2019Safety, Tolerability, and Potential Clinical Activity of a Glucocorticoid-Induced TNF Receptor-Related Protein Agonist Alone or in Combination With Nivolumab for Patients With Advanced Solid Tumors: A Phase 1/2a Dose-Escalation and Cohort-Expansion Clinical Trial
Nov 7, 2019JAMA Oncol 2019:1-8
Heinhuis Kimberley M, Schilder Russell J, O'Byrne Kenneth, Curigliano Giuseppe, Romano Emanuela, Patah Poliana, Wang Rui, Liu Yali, Bajaj Gaurav, Britschgi Christian, Paz-Ares Luis, Carlino Matteo, Jörger Markus, Di Nicola Massimo, Meniawy Tarek, Rottey Sylvie, Moreno Victor, Gazzah Anas, Delord Jean-Pierre, Siu Lillian L
Does Older Age Lead to Higher Risk for Neutropenia in Patients Treated with Paclitaxel?
Crombag M, Koolen S, Wijngaard S, Jörger M, Dorlo T, van Erp N, Mathijssen R, Beijnen J, Huitema A. Does Older Age Lead to Higher Risk for Neutropenia in Patients Treated with Paclitaxel?. Pharm Res 2019; 36:163.
Oct 15, 2019Does Older Age Lead to Higher Risk for Neutropenia in Patients Treated with Paclitaxel?
Oct 15, 2019Pharm Res 2019; 36:163
Crombag Marie-Rose B S, Koolen Stijn L W, Wijngaard Sophie, Jörger Markus, Dorlo Thomas P C, van Erp Nielka P, Mathijssen Ron H J, Beijnen Jos H, Huitema Alwin D R
[Molecularly-targeted anticancer treatments - a short appraisal]
Jörger M. [Molecularly-targeted anticancer treatments - a short appraisal]. Ther Umsch 2019; 76:179-185.
Sep 1, 2019[Molecularly-targeted anticancer treatments - a short appraisal]
Sep 1, 2019Ther Umsch 2019; 76:179-185
Jörger Markus
A Phase 1 study of BAL101553, a novel tumor checkpoint controller targeting microtubules, administered as 48-h infusion in adult patients with advanced solid tumors
Jörger M, Sessa C, Stuedeli S, Levy N, Hafner P, Lane H, Larger P, Engelhardt M, Kaindl T, Volden M, Mark M, Mantiero M, Hess D, Metaxas Y, Stathis A, von Moos R. A Phase 1 study of BAL101553, a novel tumor checkpoint controller targeting microtubules, administered as 48-h infusion in adult patients with advanced solid tumors. Invest New Drugs 2019
Aug 30, 2019A Phase 1 study of BAL101553, a novel tumor checkpoint controller targeting microtubules, administered as 48-h infusion in adult patients with advanced solid tumors
Aug 30, 2019Invest New Drugs 2019
Jörger Markus, Sessa Cristiana, Stuedeli Silvia, Levy Nicole, Hafner Peter, Lane Heidi, Larger Patrice, Engelhardt Marc, Kaindl Thomas, Volden Matthias, Mark Michael, Mantiero Mara, Hess Dagmar, Metaxas Yannis, Stathis Anastasios, von Moos Roger
Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study
Schuler M, Gajate P, Cathomas R, Rajagopalan P, Grevel J, Bender S, Boix O, Nogai H, Ocker M, Ellinghaus P, Schostak M, Park S, Cho B, Sayehli C, Navarro A, Soo R, Richly H, Cassier P, Tai D, Penel N, Nogova L, Jörger M. Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study. Lancet Oncol 2019
Aug 9, 2019Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study
Aug 9, 2019Lancet Oncol 2019
Schuler Martin, Gajate Pablo, Cathomas Richard, Rajagopalan Prabhu, Grevel Joachim, Bender Sebastian, Boix Oliver, Nogai Hendrik, Ocker Matthias, Ellinghaus Peter, Schostak Martin, Park Se Hoon, Cho Byoung Chul, Sayehli Cyrus Michael, Navarro Alejandro, Soo Ross A, Richly Heike, Cassier Philippe Alexandre, Tai David, Penel Nicolas, Nogova Lucia, Jörger Markus
A prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients
Hurkmans D, Mathijssen R, Aerts J, van der Leest C, van der Veldt A, Odink A, Jörger M, Debets R, Hoop E, Bins S, Wijkhuijs A, Schreurs M, Mercieca D, van Dijk T, Basak E, Koolen S. A prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients. J Immunother Cancer 2019; 7:192.
Jul 19, 2019A prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients
Jul 19, 2019J Immunother Cancer 2019; 7:192
Hurkmans Daan P, Mathijssen Ron H J, Aerts Joachim G J V, van der Leest Cor H, van der Veldt Astrid A M, Odink Arlette, Jörger Markus, Debets Reno, Hoop Esther Oomen-de, Bins Sander, Wijkhuijs Annemarie J M, Schreurs Marco W J, Mercieca Darlene, van Dijk Tanja, Basak Edwin A, Koolen Stijn L W
Prolonged tumor response associated with sequential immune checkpoint inhibitor combination treatment and regorafenib in a patient with advanced pretreated hepatocellular carcinoma
Jörger M, Gueller U, Bastian S, Driessen C, von Moos R. Prolonged tumor response associated with sequential immune checkpoint inhibitor combination treatment and regorafenib in a patient with advanced pretreated hepatocellular carcinoma. J Gastrointest Oncol 2019; 10:373-378.
Apr 1, 2019Prolonged tumor response associated with sequential immune checkpoint inhibitor combination treatment and regorafenib in a patient with advanced pretreated hepatocellular carcinoma
Apr 1, 2019J Gastrointest Oncol 2019; 10:373-378
Jörger Markus, Gueller Ulrich, Bastian Sara, Driessen Christoph, von Moos Roger
Antibodies as biomarker candidates for response and survival to checkpoint inhibitors in melanoma patients
Fässler M, Jörger M, Recher M, Risch L, Güsewell S, Risch M, Speiser D, Ludewig B, Levesque M, Dummer R, Siano M, Krolik M, Diem S, Mangana J, Hasan Ali O, Berner F, Bomze D, Ring S, Niederer R, Gil Cruz C, Pérez Shibayama C, Flatz L. Antibodies as biomarker candidates for response and survival to checkpoint inhibitors in melanoma patients. J Immunother Cancer 2019; 7:50.
Feb 20, 2019Antibodies as biomarker candidates for response and survival to checkpoint inhibitors in melanoma patients
Feb 20, 2019J Immunother Cancer 2019; 7:50
Fässler Mirjam, Jörger Markus, Recher Mike, Risch Lorenz, Güsewell Sabine, Risch Martin, Speiser Daniel E, Ludewig Burkhard, Levesque Mitchell P, Dummer Reinhard, Siano Marco, Krolik Michal, Diem Stefan, Mangana Joanna, Hasan Ali Omar, Berner Fiamma, Bomze David, Ring Sandra, Niederer Rebekka, Gil Cruz Cristina, Pérez Shibayama Christian Ivan, Flatz Lukas
Prognostic impact of polypharmacy and drug interactions in patients with advanced cancer
Hoemme A, Driessen C, Früh M, Thürlimann B, Wälti T, von Kameke A, Lehner C, Strasser F, Krähenbühl S, Haschke M, Barth H, Jörger M. Prognostic impact of polypharmacy and drug interactions in patients with advanced cancer. Cancer Chemother Pharmacol 2019; 83:763-774.
Jan 25, 2019Prognostic impact of polypharmacy and drug interactions in patients with advanced cancer
Jan 25, 2019Cancer Chemother Pharmacol 2019; 83:763-774
Hoemme Alexander, Driessen Christoph, Früh Martin, Thürlimann Beat, Wälti Thomas, von Kameke Alexander, Lehner Claudia, Strasser Florian, Krähenbühl Stephan, Haschke Manuel, Barth Holger, Jörger Markus